Literature DB >> 8837607

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

D I Gabrilovich1, H L Chen, K R Girgis, H T Cunningham, G M Meny, S Nadaf, D Kavanaugh, D P Carbone.   

Abstract

Inadequate presentation of tumor antigens by host professional antigen-presenting cells (APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors from the host immune system. Here, we show that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs. One factor responsible for these effects was identified as vascular endothelial growth factor (VEGF). Thus, VEGF may play a broader role in the pathogenesis of cancer than was previously thought, and therapeutic blockade of VEGF action may improve prospects for immunotherapy as well as inhibit tumor neovasculature.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837607     DOI: 10.1038/nm1096-1096

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  498 in total

Review 1.  Dendritic cells: a link between innate and adaptive immunity.

Authors:  K Palucka; J Banchereau
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

Review 2.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 3.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

4.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

5.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 6.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 7.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 8.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

9.  Serum angiogenin levels predict treatment response in patients with stage IV melanoma.

Authors:  Pia Vihinen; Minna Kallioinen; Meri-Sisko Vuoristo; Johanna Ivaska; Kari J Syrjänen; Marjo Hahka-Kemppinen; Pirkko-Liisa Kellokumpu-Lehtinen; Seppo O Pyrhönen
Journal:  Clin Exp Metastasis       Date:  2007-08-29       Impact factor: 5.150

10.  S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions.

Authors:  Anna Batistatou; Vassiliki Zolota; Chrisoula D Scopa
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.